CJ Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate CJRB-201 at 'ECCO 2025'; Clinical Entry Targeted for 2026

CJ Bioscience South Korea Germany New York

'CJRB-201', a proprietary strain of Faecalibacterium with potent its anti-inflammatory effects, has demonstrated the strongest induction of regulatory T cells (Tregs) among analyzed strains.Preclinical studies in multiple animal models confirm significant improvements in key disease indicators, including inhibition of weight loss and improvement in disease activity index.Offering a differentiated therapeutic option, CJRB-201 has shown preclinical efficacy comparable to a leading antibody-based therapy while providing superior safety and convenience of oral administration.View original content:https://www.prnewswire.co.uk/news-releases/cj-bioscience-to-present-preclinical-data-on-inflammatory-bowel-disease-pipeline-candidate-cjrb-201-at-ecco-2025-clinical-entry-targeted-for-2026-302378481.html